Citation for published version (APA):
Woodford, M. R., Sager, R. A., Marris, E., Dunn, D. M., Blanden, A. R., Murphy, R. L., ... Mollapour, M. (2017). Tumor suppressor Tsc1 is a new Hsp90 co-chaperone that facilitates folding of kinase and non-kinase clients. *The EMBO journal, 36*(24), 3650-3665. https://doi.org/10.15252/embj.201796700

**Citing this paper**
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections.

**General rights**
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.

*Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.*
*You may not further distribute the material or use it for any profit-making activity or commercial gain*
*You may freely distribute the URL identifying the publication in the Research Portal*

**Take down policy**
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
Tumor suppressor Tsc1 is a new Hsp90 co-chaperone that facilitates folding of kinase and non-kinase clients

Mark R Woodford1,2,†, Rebecca A Sager1,2,3,†, Elijah Marris1,2,3, Diana M Dunn1,2,3, Adam R Blanden2,3, Ryan L Murphy1,2, Nicholas Rensing4,5, Oleg Shapiro1,2, Barry Panaretou6, Chrisostomos Prodromou7, Stewart N Loh2,3, David H Gutmann6, Dimitra Bourboulia1,2,3, Gennady Bratslavsky1,2, Michael Wong4,5 & Mehdi Mollapour1,2,3,*

Abstract

The tumor suppressors Tsc1 and Tsc2 form the tuberous sclerosis complex (TSC), a regulator of mTOR activity. Tsc1 stabilizes Tsc2; however, the precise mechanism involved remains elusive. The molecular chaperone heat-shock protein 90 (Hsp90) is an essential component of the cellular homeostatic machinery in eukaryotes. Here, we show that Tsc1 is a new co-chaperone for Hsp90 that inhibits its ATPase activity. The C-terminal domain of Tsc1 (998–1,164 aa) forms a homodimer and binds to both protomers of the Hsp90 middle domain. This ensures inhibition of both subunits of the Hsp90 dimer and prevents the activating co-chaperone Aha1 from binding the middle domain of Hsp90. Conversely, phosphorylation of Aha1-Y223 increases its affinity for Hsp90 and displaces Tsc1, thereby providing a mechanism for equilibrium between binding of these two co-chaperones to Hsp90. Our findings establish an active role for Tsc1 as a facilitator of Hsp90-mediated folding of kinase and non-kinase clients—including Tsc2—thereby preventing their ubiquitination and proteasomal degradation.

Keywords Aha1; heat-shock protein 90; Tsc1; Tsc2; tuberous sclerosis complex

Subject Categories Protein Biosynthesis & Quality Control; Signal Transduction

Introduction

Molecular chaperones, as indicated by their names, are involved in folding, stability, and activity of many proteins also known as “client proteins” (Schopf et al., 2017). The molecular chaperone heat-shock protein 90 (Hsp90) looks after many clients (> 200 known) that are involved in tumor initiation, progression, and metastasis. Therefore, Hsp90 is recognized as a suitable target for cancer therapy (Neckers & Workman, 2012). Hsp90 chaperone function is linked to its ability to bind and hydrolyze ATP and depends on a cycle of Hsp90 conformational changes (Prodromou, 2012). Hsp90 drugs bind to the ATP-binding pocket of Hsp90 and inhibit its chaperone activity. In turn, this prevents Hsp90 association with client proteins, causing their proteasomal degradation. Unlike other anti-cancer drugs, Hsp90 inhibitors target multiple drivers of oncogenesis simultaneously.

Co-chaperones regulate Hsp90 chaperone cycle by directly interacting with Hsp90 and providing directionality to the cycle (Cox & Johnson, 2011). Additionally, certain co-chaperones, for example, HOP and Cdc37p50, decelerate or inhibit the Hsp90 chaperone cycle, loading distinct sets of clients such as steroid hormone receptors and kinases, respectively, to the Hsp90 (Verba et al, 2016). Conversely, the Aha1 co-chaperone aids in high-energy conformational modulations necessary for Hsp90 ATPase competence. This markedly increases the weak endogenous enzymatic activity of Hsp90 and establishes Aha1 as a crucial component of active Hsp90 chaperone complexes (Panaretou et al, 2002; Li et al, 2013a).

Tuberous sclerosis complex (TSC) is a rare autosomal dominant syndrome that is characterized by the development of benign tumors in various organs, including skin, brain, heart, kidneys, and
Published online: November 10, 2017

Mark R Woodford et al The new co-chaperone Tsc1 inhibits Hsp90

The EMBO Journal Vol 36 | No 24 | 2017 3651

Tsc2 is a client of Hsp70 and Hsp90

Molecular chaperones are generally involved in the folding and stability of proteins. We therefore tested whether the integrity of Tsc2 depended on the Hsp70 and Hsp90 chaperones. Endogenous Tsc2 was immunoprecipitated from HEK293 cells and it was shown to interact with both Hsp70 and Hsp90 and their co-chaperones including HOP, Cdc37p50, PP5, and p23, but not Aha1 (Figs 1A and EV1). We next showed that treating HEK293 cells with the Hsp70 inhibitor JC-98 (Fig 1B) (Li et al, 2013b), or Hsp90 inhibitors ganetespib GB (Fig 1C) (Ying et al, 2012), or SNX2112 (Fig 1D) (Barrott et al, 2013) cause the degradation of Tsc2. Surprisingly, inhibition of Hsp70 or Hsp90 did not affect the stability of Tsc1 (Fig 1B–D). It is noteworthy that we used the degradation of Akt and phospho-S473-Akt as a positive control for Hsp90 inhibition in cells, since Akt is a bona fide Hsp90 client protein.

Inhibition of Hsp70 or Hsp90 generally leads to ubiquitination and degradation of its client proteins in the proteasome (Xu et al, 1999). Treating HEK293 cells with 50 nM proteasome inhibitor bortezomib (BZ) for 2 h stabilizes Tsc2 (Fig 1E). These data suggest that Tsc2 experiences protein turnover at steady state. We next showed that treating HEK293 cells with BZ for 1 h prior to addition of GB (Hsp90 inhibitor) blocked the degradation of Tsc2 (Fig 1F).

Finally, to determine whether Tsc2 or Hsp90 inhibition leads to ubiquitination of Tsc2 prior to its degradation in the proteasome, Tsc2-FLAG was transiently expressed, immunoprecipitated, and salt-stripped (with 0.5 M NaCl) from HEK293 cells treated with either 50 nM BZ, 1 μM GB, or 10 μM JC-98 for 4 h. Tsc2 is ubiquitinated upon inhibition of Hsp70, Hsp90, or the proteasome (Fig 1G). Taken together, Tsc2 appears to be a new client of Hsp70 and Hsp90, and pharmacologic inhibition of Hsp90 leads to ubiquitination and degradation of Tsc2 in the proteasome.

The new co-chaperone Tsc1 inhibits Hsp90 ATPase activity

Tsc1 stability does not depend on Hsp70 and Hsp90; however, because of its relationship with Tsc2, we asked whether Tsc1 interacts with these two molecular chaperone machineries. We first immunoprecipitated endogenous Tsc1 from HEK293 cells and detected both Hsp70 and Hsp90 (Fig 2A). We also observed Tsc1 interaction with Hsp90 co-chaperones PP5 and Cdc37 (Fig 2A) but not Aha1, HOP, or p23 (Fig EV2A). We also co-immunoprecipitated Hsp90 client proteins Raf-1, Akt, Cdk4, glucocorticoid receptor (GR), and Tsc2 (Fig 2A). Hsp90 consists of N (amino)-, M (middle)-, and C (carboxy)-domains. To determine Tsc1 and Tsc2 interaction with these Hsp90 domains, we transiently transfected and expressed each domain with FLAG-tag in HEK293 cells. Using anti-FLAG M2 affinity gel, each Hsp90 domain was immunoprecipitated and co-immunoprecipitation of Tsc1 and Tsc2 was observed by immunoblotting. Tsc1 interacts with the Hsp90 M- and C-domains (Fig 2B), whereas Tsc2 bound only to the Hsp90 C-domain (Fig 2B). The MEEVD motif at the extreme C-terminus of Hsp90 is a highly conserved tetratricopeptide repeat (TPR) domain-binding site, which mediates interaction with many co-chaperones (Chadli et al, 2008). Deletion of MEEVD from Hsp90α (zATPR) or Hsp90β (βATPR) completely abrogated the interaction of Hsp90 with Tsc1 (Fig 2C).

We next determined the region in Tsc1 that interacts with Hsp90. Based on previous work, we decided to express FLAG-tag Tsc1-fragment-A (N-domain; amino acid 1–301), Tsc1-fragment-B (Tsc2-binding domain; amino acid 302–430), and Tsc1-fragment-D (C-domain; amino acid 998–1,164) in HEK293 cells. Our data indicate that the carboxy-domain of Tsc1 (amino acid 998–1,164 or fragment D) interacts with Hsp90α (Fig 2D). In fact, Tsc1-D-HA interacts with the middle domain of Hsp90α-FLAG (Fig 2E). It is noteworthy that we were unable to express Tsc1-fragment-C (amino acid 431–718) in HEK293 cells.

We next bacterially expressed and purified fragment D (Tsc1-D-His₆) and examined its affinity for binding to Hsp90α in the presence of ADP, AMP-PNP, and GB in vitro by fluorescently labeling Tsc1-D-His₆ with Texas Red maleimide, and measuring the K₅ by fluorescence anisotropy (Fig 2F). Our bacterially expressed and purified Hsp90α was functional based on its ATPase activity. The titration fit to a single-site binding equation with a K₅ of 0.48 ± 0.19 μM (Fig 2F). This K₅ was not significantly affected by the presence of ADP or non-hydrolyzing AMP-PNP (Fig 2F). However, the presence of GB produced a K₅ of > 5 μM, therefore suggesting Tsc1-D-His₆ binding to Hsp90 is significantly reduced in the presence of GB. Binding of bovine serum albumin (BSA) was used as a negative control (Fig EV2B).

The chaperone function of Hsp90 is linked to its ATPase activity (Panaretou et al, 1998). We therefore tested the impact of Tsc1 on Hsp90 ATPase activity. Recombinant Hsp90α and Tsc1-D-His₆ were used in the molar ratio indicated (Figs 2G and EV2C and D) in the PiPer Phosphate Assay Kit (Thermo Fisher Scientific), in the presence of ATP as substrate. Hsp90α ATPase activity was measured in vitro as previously described (see Materials and Methods; Dunn et al, 2015; Figs 2G and EV2C and D). 10 μM GB inhibited Hsp90α
Figure 1. Tsc2 is a new client of Hsp90.

A  Tsc2 was immunoprecipitated from HEK293 cell lysates using anti-Tsc2 antibody or IgG (control) and immunoblotted with indicated antibodies to confirm chaperone and co-chaperone interaction.

B  HEK293 cells were treated with 10 μM JG-98 (Hsp70 inhibitor) for the indicated times. Tsc1 protein stability and Tsc2 protein stability were assessed by Western blotting.

C, D  HEK293 cells were treated with either (C) 1 μM GB or (D) 2 μM SNX-2112 (Hsp90 inhibitors) for the indicated times. Tsc1 protein stability and Tsc2 protein stability were assessed by immunoblotting. Akt and phospho-S473-Akt were used as positive controls.

E  HEK293 cells were treated with 50 nM bortezomib (BZ) for the indicated times, and Tsc1 and Tsc2 proteins were evaluated by immunoblotting.

F  50 nM BZ was added to HEK293 cells for 1 h followed by addition of 1 μM GB for 8 h. HEK293 cells were also treated individually with BZ or GB. UN represents untreated cells. Stability of Tsc2 was examined by immunoblotting.

G  Empty vector (EV) or Tsc2-FLAG was used to transiently transfect HEK293 cells for 24 h followed by no treatment (UN), or treatment with either 50 nm BZ, 1 μM GB, or 10 μM JG-98 for 4 h. Tsc2-FLAG was immunoprecipitated, and ubiquitination was examined by immunoblotting with an anti-pan-ubiquitin antibody.

Source data are available online for this figure.
The new co-chaperone Tsc1 inhibits Hsp90

Mark R Woodford et al

ATPase activity (Fig 2G). Addition of Tsc1-D also significantly inhibited the ATPase activity of Hsp90α (Figs 2G and EV2D). Percentage ATPase activity was based on mmol P_i per mol Hsp90α per minute for Hsp90α alone and Tsc1-D was titrated until inhibition was achieved (Hsp90α = 300 nM, Tsc1-D = 1000 nM). We repeated the experiments in Fig 2G using BSA as a negative control (Fig EV2E).

To obtain further evidence that Tsc1 is a regulator of Hsp90 ATPase activity, we used previously created Cre knockout (Tsc1\(^{\text{GFP/Cre}}\)) mice with conditional inactivation of the TSC1 gene predominantly in glia (Uhlmann et al, 2002; Zeng et al, 2008) Brain tissue was harvested from Tsc1\(^{\text{GFP/Cre}}\) (Tsc1\(^{\text{flox/box}}\)-GFP-Cre) mice, as well as Tsc1\(^{\text{box/box}}\)+-GFP-Cre and Tsc1\(^{\text{flox/box}}\) littermate controls (Uhlmann et al, 2002; Zeng et al, 2008). Hsp90 was isolated from Tsc1\(^{\text{GFP/Cre}}\) and control brains (Fig EV2F). PiPer Phosphate Assay was used to measure the isolated Hsp90 ATPase activity. Our data show that the conditional knockout of Tsc1 in mouse brain caused a significant increase in ATPase activity compared to the control samples (Fig 2H). Compromised Hsp90 chaperone function impacts the stability and/or the activity of its client proteins. We therefore examined the stability of a selection of client proteins in lysates prepared from Tsc1\(^{\text{GFP/Cre}}\) and control mouse brains by immunoblotting. Conditional inactivation of Tsc1 in mouse brains caused a down-regulation of the kinase clients such as ErbB2 and Ulk1 and non-kinase client proteins such as estrogen receptor (ER) and GR (Fig 2I).

Our data suggest that Tsc1 is a co-chaperone of Hsp90 and a potent inhibitor of the chaperone cycle. Furthermore, Tsc1 co-chaperone can influence and impact the stability and activity of a large number of Hsp90 client proteins.

**Tsc1 co-chaperone enables Tsc2 binding to Hsp90**

To gain further insight into Tsc1 function as a new co-chaperone of Hsp90, we examined a selection of its bona fide clients in wild-type and TSC1-deficient (Tsc1\(^{-/-}\)) murine embryonic fibroblast (MEF) cells lines. Absence of Tsc1 significantly reduced both the activity and the stability of kinase clients phospho-Y416-c-Src, total c-Src, ErbB2, Ulk1, Raf-1, and Cdk4, and non-kinase clients phospho-S211-GR, total GR, FLCN, and Tsc2 (Fig 3A). To determine the effects of Tsc1 over-expression on the Hsp90 clients, HEK293 cells were transiently transfected with either 2 or 4 μg of Tsc1-HA-tagged plasmid. Over-expression of Tsc1 also caused a reduction in the stability of the Hsp90 kinase clients such as ErbB2, Ulk1, and Raf-1 (Fig 3B). Conversely, high levels of Tsc1 increased the total amount of GR (Fig 3B), but did not impact the stability of Cdk4 kinase. It also had a slight positive impact on the stability of both FLCN and Tsc2 (Fig 3B). Tsc1 co-expression with Hsp90 impacts by assessing the steady-state expression of cystic fibrosis transmembrane conductance regulator (CFTR). CFTR is a client protein of Hsp90 (Youker et al, 2004; Wang et al, 2006) and relies on the Hsp90 chaperone cycle for correct folding (Youker et al, 2004; Wang et al, 2006). HEK293 cells were transiently co-transfected with CFTR and either pcDNA3 (control) or Tsc1-FLAG plasmids. Immunoblot analysis of these samples using anti-CFTR antibody showed a doublet (Fig 3C). The upper band is the mature Golgi-processed glycoform of CFTR located at the cell surface and the lower band an immature core-glycosylated protein (Fig 3C). Over-expression of Tsc1 significantly increased CFTR protein, suggesting a deceleration in Hsp90 chaperone activity and, consequently, an increase in CFTR expression. Our data provide further evidence that Tsc1 functions as a new co-chaperone of Hsp90, and its levels compromise Hsp90 chaperoning of client proteins.

We next explored the role of Tsc1 in Hsp90-mediated chaperoning of the Tsc2 client protein. We managed to express and purify a small amount of Tsc1 and Tsc2 from HEK293 cells. Tsc1 directly associates with bacterially expressed and purified Hsp90α-His\(_6\) (Fig 3D) and Tsc2 (Fig 3E). Surprisingly, direct interaction of Tsc2 and Hsp90α-His\(_6\) did not occur in vitro; however, pre-incubation of Hsp90α-His\(_6\) with Tsc1 facilitated the formation of Hsp90α:Tsc1:Tsc2 complex (Fig 3F). To explore whether Tsc2 may directly interact with Hsp90 in this trimeric complex, we first showed that treating the Tsc1:Hsp90 complex with Hsp90 inhibitor GB did not disrupt Hsp90 interaction with Tsc1 (Fig 3G). The interaction of Tsc1:Tsc2 was also not disrupted with GB (Fig 3H). However, treating the trimeric Tsc1:Tsc2:Hsp90α complex with GB led to dissociation of Tsc2 from the complex (Fig 3I), whereas Tsc1:Hsp90 interaction from these treated samples was unaffected (Fig 3J). It is
The new co-chaperone Tsc1 inhibits Hsp90

Mark R Woodford et al

Figure 2.
noteworthy that we were unable to produce large amounts of Tsc1 and Tsc2 proteins from bacteria, yeast, or baculovirus expression systems for biophysical analysis. Taken together, our data, at least qualitatively, suggest that the co-chaperone Tsc1 acts as a loading scaffold facilitating the direct binding of Tsc2 to Hsp90 (Fig 3K).

In terms of the clinical relevance of our findings, we explored the pathogenic mutant L117P, which is in the amino-terminus domain of Tsc1 but not within the Tsc2-binding domain. In agreement with previous works (Hoogeveen-Westerveld et al, 2010, 2012), the L117P-Tsc1-HA is unstable when transiently expressed in the Tsc1−/− MEF cell line. However, over-expression of this mutant (i.e., using 6 μg L117P-Tsc1-HA plasmid for transfection) slightly stabilized the L117P-Tsc1 as well as Tsc2 in the Tsc1−/− MEF cells (Fig EV3A). We next showed that transfection of the Tsc1−/− MEF cells with either 1 μg of empty vector or L117P-Tsc1-HA plasmid for 24 h and followed by treatment with 50 nM proteasome inhibitor BZ led to increased stability of L117P-Tsc1-HA (Fig EV3B). Finally, we overexpressed (6 μg L117P-Tsc1-HA plasmid) in Tsc1−/− MEF cells followed by immunoprecipitation and detection of Tsc2 and Hsp90 Co-IP by immunoblotting (Fig EV3C). Our findings here suggest that loss of Tsc1 as the result of mutation in its N-domain destabilizes Tsc1 and therefore prevents Tsc2 from binding to Hsp90. This makes Tsc2 susceptible to proteasome-mediated degradation.

The co-chaperone Tsc1 binds to the closed conformation of Hsp90

Some co-chaperones have been shown to impact the affinity of Hsp90 for binding to ATP or amino-domain inhibitors of Hsp90 both in vitro and in vivo (Walton-Diaz et al, 2013). Here we used the wild-type and Tsc1−/− MEF cell lines and showed that absence of Tsc1 significantly reduces Hsp90 binding to ATP-agarose (Fig 4A). Conversely, over-expression of Tsc1-HA or its Hsp90-binding fragment Tsc1-D-FLAG in HEK293 cells increased Hsp90 binding to ATP-agarose (Fig 4B and C). We obtained similar results with the Hsp90 inhibitor GB, where lack of Tsc1 in MEF cells significantly reduced the binding of Hsp90 to 1 μM biotinylated GB (Fig 4D). However, over-expression of Tsc1-HA or Tsc1-D-FLAG in HEK293 cells increased the binding of Hsp90 to 0.1 μM biotinylated GB (Fig 4E and F). Taken together, our results suggest that Tsc1 increases the binding of Hsp90 to ATP and its inhibitor GB.

Hsp90 ATPase activity is coupled to a conformational cycle in which the Hsp90 dimer progresses from an N-terminally “open” state to a closed conformation. Human Hsp90α-E47A and D93A mutants can promote either “closed” or “open,” respectively (Panaretou et al, 1998). These two mutants and wild-type Hsp90α-FLAG were transiently expressed and immunoprecipitated from HEK293 cells. Tsc1 interacts with both Hsp90α-FLAG and the E47A mutant. However, Tsc1 binding with the “open” conformation mutant D93A was reduced (Fig 4G). We repeated these experiments with Tsc1-D-HA and show that this fragment binds with the same affinity to the wild-type Hsp90α-FLAG, E47A, and D93A mutants (Fig 4H). These data suggest that the Tsc1-D fragment, which binds to the Hsp90 middle domain (Fig 2E), associates with Hsp90, and the “open” or “closed” conformations do not impact this interaction.

Tsc1 dimer binds to both protomers of the Hsp90 middle domain

Our initial data revealed that Tsc1 inhibits Hsp90 chaperone function (Fig 2G) and also that Tsc1 is not in a same complex as Aha1 (Fig EV2A). To gain further insight into the mechanism of Tsc1 competition with Aha1 for binding to Hsp90, we first showed that Hsp90 binds stronger to Aha1 in the absence of Tsc1 in MEF cells (Fig 5A). Our previous work showed that phosphomimetic Hsp90α-Y313E has a stronger affinity for binding to Aha1 than wild-type Hsp90 (Xu et al, 2012). Here, we showed that Hsp90α-Y313E does not interact with Tsc1 (Fig 5B). We next explored whether Tsc1 binds to the same amino acids in the middle domain of Hsp90 that are occupied by Aha1. This was achieved using the V410E-FLAG mutant, because this residue is known to participate in the interaction of Aha1-N with the middle domain of Hsp90 (Retzlaff et al, 2010). Like Aha1, Tsc1 interaction with Hsp90α-V410E (Fig 5C) was completely abrogated. Previous work has shown that Aha1 binds in
The new co-chaperone Tsc1 inhibits Hsp90

Figure 3.
an asymmetric manner to an Hsp90 dimer (Retzlaff et al., 2010). To test whether Tsc1 also binds to Hsp90 in a similar manner as Aha1, we transiently co-expressed both Hsp90a-FLAG and Hsp90a-HA in HEK293 cells. Following immunoprecipitation with anti-FLAG M2 affinity gel, Hsp90a-FLAG was competed from the agarose with FLAG peptide and then subjected to a second round of immunoprecipitation using HA-agarose. The isolated Hsp90 (WT-FLAG:WT-HA) is a homodimer with one protomer tagged with FLAG and the other protomer with HA. We were able to co-immunoprecipitate Tsc1 and Aha1 with Hsp90α-FLAG:HA (Fig 5D). We also carried out similar experiment with the exception of co-expressing Hsp90α-V410E-FLAG with Hsp90α-HA in HEK293 cells. The isolated Hsp90α (V410E-FLAG:WT-HA) consists of an Hsp90α-FLAG-V410E protomer and a second subunit with the wild-type Hsp90α-HA (Fig 5D). We co-immunoprecipitated Aha1 in this sample, which is in agreement with Aha1 interaction with one subunit of the Hsp90 dimer (Fig 5D; Retzlaff et al., 2010; Mollapour et al., 2014). Tsc1 however did not bind to Hsp90α-V410E-FLAG:WT-HA, suggesting

![Image](image-url)
that Tsc1 interacts symmetrically with both subunits of the Hsp90 dimer.

Our initial data identified that region D within Tsc1 (Tsc1-D) binds to the middle domain of Hsp90α (Fig 2E). We next confirmed that as with the full-length Tsc1, Tsc1-D does not co-immunoprecipitate Aha1 from HEK293 cells (Fig 5E). We also showed that Tsc1-D exists as a homodimer, by first co-expressing Tsc1-D-FLAG and Tsc1-D-HA in HEK293 cells. Immunoprecipitation of Tsc1-D-FLAG led to co-immunoprecipitation of Tsc1-D-HA (Fig 5F). We next bacterially expressed and purified Tsc1-D-His6. Gel filtration of the purified protein indicates that Tsc1-D-His6 exists as a dimer in solution, as it migrates with an apparent size of approximately twice the predicted molecular weight of the monomer (22.1 kDa; Fig 5G).

To dissect the competitive binding of Aha1 and Tsc1 to Hsp90, we first bound bacterially expressed and purified Tsc1-D-His6 to Ni-NTA agarose and then incubated with 100 ng recombinant Hsp90α. After washing the Ni-NiTA agarose with the wash buffer, we added different amounts of recombinant Aha1-FLAG. We found that addition of 200 ng recombinant Aha1-FLAG completely disrupted Hsp90α and Tsc1-D-His6 interaction (Fig 5H). We next used a similar experiment by first binding Aha1-FLAG to anti-FLAG M2 affinity gel followed by addition of 100 ng recombinant Hsp90α to form an Aha1-Hsp90α complex. After washing the agarose beads with the wash buffer, different amounts of Tsc1-D-His6 were added to the complex. Our data show that addition of 1 ng Tsc1-D-His6 was sufficient to completely disrupt the Aha1-Hsp90α complex (Fig 5I). These data indicate that Tsc1 has a stronger affinity for association with Hsp90 than Aha1. Lastly, we tested the simultaneous impact of both Tsc1 and Aha1 on Hsp90 ATPase activity. Our data show that Aha1 stimulates and Tsc1 inhibits Hsp90α ATPase (Figs 5J and EV4A and B). We also show that addition of 1.3 μM Aha1 to Hsp90α after incubation with 1 μM Tsc1 was capable of stimulating Hsp90α ATPase to approximately 100% (Figs 5J and EV4B). Our data suggest that Tsc1 and Aha1 compete for binding to the same sites in the middle domain of Hsp90 in order to fine-tune its ATPase activity.

Phosphorylation of Aha1 displaces Tsc1 from Hsp90

We previously showed that c-Abl-mediated phosphorylation of Aha1-Y223 promotes its interaction with Hsp90 (Dunn et al., 2015). We therefore examined the influence of phospho-Aha1-Y223 on Tsc1 binding to Hsp90. We bound Tsc1-D-His6 to Ni-NiTA agarose and incubated with 100 ng recombinant Hsp90α. After washing the agarose with buffer, we added different amounts of Aha1-Y223E-FLAG. Our data show that addition of 1 ng of phosphomimetic Y223E mutant completely dissociated Hsp90α from Tsc1-D-His6 (Fig 6A) as opposed to 200 ng WT Aha1 (Fig 5H). Tsc1 has no similarities with other proteins and although orthologs can be found in most eukaryotic cells, including the fission yeast Schizosaccharomyces pombe, no TSC1 gene exists in Saccharomyces cerevisiae. We used this system to express TSC1-FLAG under galactose-inducible promoter GAL1 in yeast containing either human Hsp90α or yeast Hsp82 (yHsp90) as the sole functional Hsp90. Tsc1-FLAG was detectable only in S. cerevisiae containing Hsp90α (Fig 6B) and this expression caused lethality in yeast cells (Fig 6C). We next used this strain to transform an empty vector and Tsc1-FLAG to form an Aha1:Hsp90α complex. After washing the agarose beads with the wash buffer, different amounts of Tsc1-D-His6 were added to the complex. Our data show that addition of 1 ng Tsc1-D-His6 was sufficient to completely disrupt the Aha1-Hsp90α complex (Fig 5I). These data indicate that Tsc1 has a stronger affinity for association with Hsp90 than Aha1. Lastly, we tested the simultaneous impact of both Tsc1 and Aha1 on Hsp90 ATPase activity. Our data show that Aha1 stimulates and Tsc1 inhibits Hsp90α ATPase (Figs 5J and EV4A and B). We also show that addition of 1.3 μM Aha1 to Hsp90α after incubation with 1 μM Tsc1 was capable of stimulating Hsp90α ATPase to approximately 100% (Figs 5J and EV4B). Our data suggest that Tsc1 and Aha1 compete for binding to the same sites in the middle domain of Hsp90 in order to fine-tune its ATPase activity.

Figure 5. Tsc1 dimer binds to both protomers of Hsp90 middle domain.

A Hsp90α was isolated from wild-type and Tsc1+/− MEY cells lysates using anti-Hsp90α/β antibody and immunoblotted with Aha1 antibody.
B Hsp90α-FLAG and the phosphomutants Y313F and Y313E were transiently expressed and isolated from HEK293 cells. Co-immunoprecipitation of Tsc1 and Aha1 was examined by immunoblotting.
C Hsp90α-FLAG and V410E mutant were transiently expressed and isolated from HEK293 cells. Co-immunoprecipitation of Tsc1 and Aha1 was examined by immunoblotting.
D Hsp90α-FLAG and Hsp90α-HA were co-expressed in HEK293 cells. Hsp90α-FLAG was first isolated by anti-FLAG M2 affinity gel and then competed with FLAG peptide. Hsp90α-FLAG-Hsp90α-HA heterodimer protein was isolated by second immunoprecipitation using HA-agarose. Co-immunoprecipitation of Tsc1 and Aha1 was examined by immunoblotting.
E HEK293 cells transiently expressed Tsc1-D-FLAG. Immunoprecipitation of Tsc1-D-FLAG and co-immunoprecipitation of Hsp90 and Aha1 were examined by immunoblotting.
F Tsc1-D-FLAG and Tsc1-D-HA were co-expressed in HEK293 cells. Tsc1-D-FLAG was immunoprecipitated, and co-immunoprecipitation of Tsc1-D-HA was examined by immunoblotting.
G Bacterially expressed Tsc1-D-His6 was concentrated to 10 mg/ml and subjected to gel filtration using a Superdex 75 column. The protein migrates as a monodisperse peak with an apparent MW of ~52 kDa.
H Tsc1 and Aha1 compete for binding to Hsp90α. Tsc1-D-His6 was attached to Ni-NiTA agarose and then incubated with Hsp90α. Ni-NiTA agarose was then washed and incubated with the indicated amounts of Aha1-FLAG.
I Aha1-FLAG attached to anti-FLAG M2 affinity gel was incubated with Hsp90α initially and then washed and incubated with Aha1-Y223E-FLAG and incubated with indicated amounts of the Tsc1-D-His6.
J Tsc1-D-His6 binds to Hsp90α ATPase activity after 30 min. Addition of 1.3 μM Aha1-FLAG stimulated the ATPase activity. All the data represent mean ± SD of three biological replicates. Student’s t-test was performed to assess statistical significance (*P < 0.05, **P < 0.0005).

Source data are available online for this figure.
Figure 5.

Mark R Woodford et al. The new co-chaperone Tsc1 inhibits Hsp90. The EMBO Journal. Vol 36 | No 24 | 2017

Published online: November 10, 2017
Hsp90 binds to both Aha1 and Tsc1 (presumably separate complexes) in the wild-type MEF cells (Fig 6F). DPH-mediated activation of c-Abl and hyperphosphorylation of Aha1 in the wild-type MEF cells increased Hsp90 binding to Aha1 but abrogated its interaction with Tsc1 (Fig 6F). Hsp90 also bound stronger to Aha1 in Tsc1−/− MEF cells (Fig 6F). We repeated the same experiment but treated the MEF cells with 5 μM GNF-5 (a selective allosteric c-Abl inhibitor) for 24 h (Yang et al., 2011). Inhibition of c-Abl in wild-type MEF cells reduced phosphorylation of Aha1 and its association with Hsp90 and led to enhanced interaction of Tsc1 with Hsp90 (Fig 6G). Interestingly, Aha1 did not dissociate from Hsp90 in Tsc1−/− MEF cells treated with GNF-5 (Fig 6G). These data suggest that Tsc1 plays an essential role in dissociation of Aha1 from Hsp90 in cells.

We further explored the role of c-Abl-mediated phosphorylation of Aha1 and its competition with Tsc1 for binding to Hsp90 by using the c-Abl−/− MEF cells. Absence of c-Abl in this MEF cell line, and therefore lack of Aha1-Y223 phosphorylation, abrogated Aha1 interaction with Hsp90, which is consistent with our previous work (Dunn et al., 2015; Fig 6H). Conversely, Tsc1 binding to Hsp90 was enhanced in the c-Abl−/− MEF cells compared to the wild-type MEF cells (Fig 6H). Lastly, silencing of TSC1 by siRNA in c-Abl−/− MEF cells restored Aha1 binding with Hsp90 (Fig 6I, Appendix Table S1). Taken together, our data here suggest a dynamic equilibrium in binding of Aha1 and Tsc1 to Hsp90 that can be influenced in part by phosphorylation of Aha1.

Discussion

Mutations in either the TSC1 or TSC2 tumor suppressor genes cause TSC, which is a genetic syndrome that leads to manifestation of benign tumors in the brain and other organs such as kidneys, heart, eyes, lungs, and skin. Tsc1 and Tsc2 form a physical and functional complex that ultimately inhibits mTOR. Tsc2 is a GTPase-activating protein, and Tsc1 prevents Tsc2 interaction with HERC1 ubiquitin ligase (Crino et al., 2006; Henske et al., 2016). Previous work has also shown that Tsc1 and Tsc2 both interact with the co-chaperone complex R2TP/Prefoldin-like (R2TP/PFDL) complex (Cloutier et al., 2017). In this study, we demonstrate that Tsc2 is a client of the molecular chaperones Hsp70 and Hsp90, since treating the cells with Hsp70 or Hsp90 inhibitors leads to Tsc2 ubiquitination and proteasomal degradation. We further demonstrate that Tsc1 is a new co-chaperone of Hsp90. Tsc1 carboxy-domain (998–1,164 aa; Tsc1-D) exists as a homodimer and interacts with the middle domain of Hsp90. 100 nM of Tsc1-D is sufficient to inhibit or decelerate Hsp90 ATPase activity by 72%. Conversely, Hsp90 isolated from mouse brains with conditional inactivation of Tsc1 had a higher ATPase activity compared to the Hsp90 from control samples. Furthermore, inactivation of Tsc1 in these samples caused a down-regulation of the kinase clients such as ErbB2 and Ulk1 as well as non-kinase client proteins such as estrogen receptor (ER) and GR. This is consistent with our findings obtained from the Tsc1−/− MEF cells, which showed down-regulation of kinase clients such as ErbB2, Ulk1, c-Src, Raf1, and Cdk4 and non-kinase clients such as GR, FLCN, and Tsc2. Over-expression of Tsc1 in HEK293 cells also down-regulated the kinase clients but surprisingly stabilized the steroid hormone receptors and non-kinase clients such as FLCN and CFTR possibly because of the slow chaperone cycle of Hsp90. Our findings suggest that the newly identified function of Tsc1 is to regulate the chaperoning of Hsp90 clients including Tsc2. Like other co-chaperones such as Cdc37 and HOP, Tsc1 behaves as a scaffold in order to load clients, in this case Tsc2, to Hsp90. It is also conceivable that Tsc1 regulates the chaperone function of Hsp70 and perhaps like HOP, connects the transfer of clients between Hsp70 and Hsp90.

Previous works have shown that pathogenic missense mutations of Tsc1 in its N-domain can destabilize the Tsc1 protein (Hoogeveen-Westerveld et al., 2010, 2012). We have shown that the pathogenic mutant L117P-Tsc1 is unstable and also prevents Tsc2 from binding to Hsp90. This leads to destabilization of Tsc2 and perhaps proteasome-mediated degradation.

What is the mechanism of Tsc1 interaction with and inhibition of Hsp90? Hsp90 chaperone cycle is linked to its ability to bind and hydrolyze ATP (Panaretou et al., 1998). This provides a series of conformational changes in which the Hsp90 dimer progresses from an N-terminally “open” state to a “closed” conformation. Tsc1 prefers binding to the closed conformation mutant D93A rather than the open state mutant D93A. While the Tsc1-D fragment interacts

Figure 6. Phosphorylation of Aha1 displaces Tsc1 from Hsp90.

A Tsc1-D-His6 was attached to Ni-NTA agarose and then incubated with Hsp90x. Ni-NTA agarose was then washed and incubated with the indicated amounts of phosphonimetic Aha1-Y223E-FLAG.

B PP3 yeast strain expressing either yHsp90 or Hsp90x as the sole copies of Hsp90 was transformed by GAL1-TSC1-FLAG and grown on raffinose (Raf) overnight. The cells were shifted to galactose (Gal) media for 4 h. Expression of Tsc1-FLAG was assessed by immunoblotting. Sba1 was used as a loading control.

C Strains in (B) were spotted at 1:10 dilution series on YPED or YPGal media. Plates were incubated at 30°C for 2 days.

D Yeast strains in (B) were also transformed with ADH1-AHA1 or the phosphonimetic mutant Y223E. Cells were grown in similar conditions as (B) and the expression of Aha1, Tsc1-FLAG, and Hsp90x was examined by immunoblotting.

E Yeast strains from (D) were spotted at 1:10 dilution series on YPED or YPGal media. Plates were incubated at 30°C for 2 days.

F Wild-type and Tsc1−/− MEF cells were treated with 20 μM DPH (c-Abl activator) for 6 h prior to lysis. Hsp90 (Hsp90x/[β]) was immunoprecipitated, and co-immunoprecipitation of Aha1 and Tsc1 was examined by immunoblotting.

G Wild-type and Tsc1−/− MEF cells were treated with 5 μM GNF-5 (c-Abl inhibitor) for 24 h prior to lysis. Hsp90 (Hsp90x/[β]) was immunoprecipitated, and co-immunoprecipitation of Aha1 and Tsc1 was examined by immunoblotting.

H Hsp90 (Hsp90x/[β]) was immunoprecipitated from wild-type and c-Abl−/− MEF cell lysate. Co-immunoprecipitation of Aha1 and Tsc1 was examined by immunoblotting.

I Hsp90 (Hsp90x/[β]) was immunoprecipitated from c-Abl−/− MEF with siRNA knockdown of TSC1. Co-immunoprecipitation of Aha1 and Tsc1 was examined by immunoblotting.

Source data are available online for this figure.
Figure 6.
with the middle domain of Hsp90, deletion of the MEEVD motif (the TPR domain-binding site) at the very C-terminus of Hsp90 completely abrogates Tsc1 binding to Hsp90. Our data suggest that the binding of Tsc1 to Hsp90 is complex, and it requires multiple surfaces of Tsc1 to interact with Hsp90. Tsc1 is also not in the same Hsp90 complex with Aha1, p23, or HOP co-chaperones. Because Tsc1 and the co-chaperone Aha1 both bind the middle domain and do not exist in the same Hsp90 complex, we examined Aha1 binding site mutants for Tsc1 interaction. Hsp90α-V410 participates in the interaction of Aha1-N with the middle domain of Hsp90 (Meyer et al., 2004). The Hsp90α-V410E mutant does not bind to either Aha1 or Tsc1. Interestingly, although V410E mutation of only one protomer of the Hsp90 middle domain binds to Aha1, this mutant does not interact with Tsc1. We conclude that a Tsc1 dimer needs to bind to both protomers of the Hsp90 middle domain. This observation also provides an explanation for Tsc1 competing with and masking Aha1 and p23 binding to Hsp90 (Fig 7). Because Tsc1 interacts with the Aha1 binding sites on Hsp90 middle domain, we predict that Tsc1 prevents the conformational changes in the catalytic loop of Hsp90 that stops the release of R400 from its retracted inactivating conformation consequently inhibiting Hsp90 ATPase activity.

Tsc1 has a high affinity for Hsp90 and significantly increases Hsp90 binding to nucleotides or N-domain inhibitors. In contrast, almost 200-fold more Aha1 protein is required to displace Tsc1-D from Hsp90 in vitro. We have previously shown that c-Abl phosphorylation of Aha1-Y223 displaces Tsc1 from Hsp90. The phosphomimetic Aha1-Y223E binds with similar affinity as Tsc1 to Hsp90, therefore providing a mechanism for equilibrium between these two co-chaperones with respect to binding to Hsp90 (Fig 7). These results establish an active role for Tsc1 as a facilitator of Hsp90 chaperoning of kinase and non-kinase clients, including Tsc2 therefore preventing their ubiquitination and degradation in the proteasome.
This work provides an explanation of how Tsc1 is involved in the stability of Tsc2 specifically as well as a broader function for Tsc1 as a new co-chaperone of Hsp90. We show here that loss of Tsc1 leads to dysregulation of Hsp90 chaperone function and instability of its client proteins, including Tsc2. It is unclear what effect inactivation of Tsc1 and the resultant hyperactive Hsp90 have on maintaining protein homeostasis in tumors in TSC. This crucial point in TSC biology warrants further study.

Materials and Methods

Mice

All the mice experiments were performed under the ethical guidelines of the Washington University School of Medicine, and animal protocols were reviewed and approved by the Washington University School of Medicine Institutional Animal Care and Use Committee (IACUC #A-3381-01; Protocol #20160091). All mice used in this study were obtained from an existing breeding colony of Tsc1^{GFAP.CKO} mice (Uhlmann et al., 2002; Zeng et al., 2008) in the animal facility of the Washington University School of Medicine.

Plasmids

pcDNA3–Tsc1–HA and pcDNA3–Tsc2–FLAG vectors were purchased from Addgene. Tsc1-FLAG was subsequently subcloned into pcDNA3.1 and the 2 μ yeast expression plasmid pYES2 (Appendix Table S1). Primers for the creation of Tsc1 domain-specific plasmids and L117P point mutation can also be found in the primer table. The empty vectors (EV) containing these tags were used and also referred to as controls. Hsp90 mutants lacking the TPR domain and point mutants were developed by PCR (Appendix Table S1). Hsp90α domain-specific plasmids were previously generated by M.R.W. (Woodford et al., 2016b). Human Aha1 and Aha1-Y223E mutant were previously cloned into pcDNA3 (Dunn et al., 2015). They were subcloned into 2 μ yeast expression plasmid p424ADH (ATCC® 87373™).

Yeast strains and growth media

Yeast strains listed in Appendix Table S1 were grown on YPDA (2% (w/v) Bacto peptone, 1% yeast extract, 2% glucose, 20 mg/l adenine), YPGal (2% (w/v) Bacto peptone, 1% yeast extract, 2% galactose, 20 mg/l adenine), and YPRaf (2% (w/v) Bacto peptone, 1% yeast extract, 2% raffinose, 20 mg/l adenine). Selective growth was on dropout 2% glucose (DO) medium with appropriate amino acids (Adams et al., 1997). Medium pH was adjusted to 6.8 with NaOH before autoclaving.

Mammalian cell culture

Cultured cell lines human embryonic kidney (HEK293), wild-type, Tsc1^{−/−} cells, and c-Abl^{−/−} MEF cells were grown in Dulbecco’s modified Eagle’s medium (DMEM, Sigma-Aldrich) supplemented with 10% fetal bovine serum (FBS, Sigma-Aldrich). HEK293 were acquired from American Type Culture Collection (ATCC). All cell lines were maintained in a CellQ incubator (Panasonic Healthcare) at 37°C in an atmosphere containing 5% CO2.

Bacterial expression and protein purification

Hsp90α-His6 was expressed and purified as previously described (Woodford et al., 2016a). The plasmid coding for Tsc1-D was transformed into E. coli strain Tuner pLYSS and grown on agar plates containing Luria broth (LB), 34 mg/l chloramphenicol, and 50 mg/l ampicillin overnight. Colonies were picked and grown in LB with 34 mg/l chloramphenicol and 200 mg/l ampicillin at 37°C with continuous 200 rpm shaking until OD600 = 0.6. The temperature was then dropped to 18°C and cells were incubated with 100 mg/l IPTG for 18 h. Cells were then harvested by centrifugation, lysed enzymatically, and purified by Ni2+-NTA chromatography (Qiagen) using a single step gradient (20 mM Tris pH 7.5, 300 mM NaCl, 10 mM β-ME, 10–250 mM imidazole). The protein was then dialyzed against 20 mM Tris pH 7.5, 10 mM 10 mM β-ME at 4°C overnight. A mild precipitate formed, which was removed by centrifugation. Proteins were > 90% pure by SDS–PAGE. Concentrations were determined using calculated extinction coefficients as previously described (Gasteiger et al., 2003). Proteins were flash-frozen on dry ice and stored at −80°C until use.

Protein extraction, IP, and immunoblotting

Protein extraction from both yeast and mammalian cells was carried out using methods previously described (Woodford et al., 2016b). For immunoprecipitation, mammalian cell lysates were incubated with anti-FLAG antibody-conjugated beads (Sigma) for 2 h at 4°C. Pulldowns were achieved by incubating lysate with Ni-NTA agarose (Qiagen) for 2 h at 4°C, or with anti-Hsp90 antibody (835-16F1, Enzo Life Sciences), or Tsc1 or Tsc2 (Cell Signalling) for 1 h followed by protein G agarose for 2 h at 4°C. Immunopellets were washed four times with fresh lysis buffer (20 mM HEPES (pH 7.0), 100 mM NaCl, 1 mM MgCl2, 0.1% NP-40, protease inhibitor cocktail (Roche), and PhosSTOP (Roche)) and eluted in 5× Laemmli buffer. For purification, immunopellets were washed four times with fresh high salt lysis buffer (20 mM HEPES (pH 7.0), 500 mM NaCl, 1 mM MgCl2, 0.1% NP-40, protease inhibitor cocktail (Roche), and PhosSTOP (Roche)) and subsequently competed off with 3× FLAG peptide (Sigma-Aldrich). Proteins bound to Ni-NTA agarose were washed with 50 mM imidazole in lysis buffer [20 mM Tris–HCl (pH 7.5), 100 mM NaCl, protease inhibitor cocktail (Roche), and PhosSTOP (Roche)] and eluted with either 300 mM imidazole in lysis buffer or with 5× Laemmli buffer. Precipitated proteins were separated by SDS–PAGE and transferred to nitrocellulose membranes as previously described (Woodford et al., 2016b). Co-immunoprecipitated proteins were detected by immunoblotting as previously demonstrated (Woodford et al., 2016b). Dilutions of antibodies are indicated in Appendix Table S1.

Protein labeling and Kd measurements

Protein labeling and Kd measurements were carried out using methods previously described (Woodford et al., 2016b). Tsc1-D was desalted into 20 mM Tris pH 7.5, 150 mM NaCl, and 1 mM TCEP using a PD-10 desalting column (GE Healthcare Bio-Sciences Marlborough, MA) and labeled with Texas Red C2 maleimide per the manufacturer’s instructions (Thermo Fisher Scientific, Grand Island,
NY). Labeling stoichiometry was 0.8 labels/Tsc1-D using $e_{955} = 104,000$ M$^{-1}$ cm$^{-1}$ for Texas Red and a correction factor of $0.26 \times e_{955}$ to account for its absorbance at 280 nm. Hsp90$_{\alpha}$ at the indicated concentrations was incubated on ice in 50 mM Tris pH 7.2, 150 mM NaCl, 1 mM TCEP, 4 mM MgCl$_2$ with or without 1 mM ATP, ADP, AMP-PNP or 1 mM GB for 10 min and then incubated with 1 µM labeled Tsc1-D for 30 min. Fluorescence anisotropy was measured using a SpectraMax i3 equipped with rhodamine fluorescence polarization module ($\lambda_{ex} \lambda_{em} = 535$ nm/595 nm) (Molecular Devices, Sunnyvale, CA). Curve fitting was done in SigmaPlot 10.0.

**Hsp90 ATPase activity measurement**

Purified Hsp90 protein was quantified by Micro BCA™ Protein Assay Kit (Thermo Scientific) and 2.5 µg Hsp90$_{\alpha}$ was assayed in triplicate as outlined in the P,Per™ Phosphate Assay Kit (Life Technologies) and previously described (Dunn et al., 2015). ATP turnover was calculated as mmol P$_i$ per mol Hsp90$_{\alpha}$ per minute, and relative ATPase activity was calculated from those values, with the value of Hsp90$_{\alpha}$ alone representing 100% activity.

**Quantification and statistical analysis**

The data presented are the representative or examples of three biological replicates unless it is specified. Data were analyzed with unpaired t-test. Asterisks in figures indicate significant differences ($^*P < 0.05$, $^{**}P < 0.005$, $^{***}P < 0.0005$, and $^{****}P < 0.00001$). Error bars represent the standard deviation (SD) for three independent experiments, unless it is indicated.

**Expanded View** for this article is available online.

**Acknowledgments**

We are indebted to Dr. David J. Kwiatkowski (Brigham and Women’s Hospital) and Dr Brendan D. Manning (Harvard School of Public Health) for their comments and advice on the manuscript. We are grateful to Dr. Kwiatkowski for Tsc1-/- MEF cell line, Dr. Stephen Goff (Columbia University) for c-Abl-/- MEF cell line, Dr. Bradsky (University of Pittsburgh) for CFTR plasmid, Dr. Timothy Haystead (Duke University) for SNX-2112, and Dr. Jason Gestwicki for GC-98 (University of California San Francisco). This work was supported by the National Institute of General Medical Sciences of the National Institutes of Health under Award Number RO1GM124256 (M.M.). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. This work was also supported by the Wellcome Trust 099605/S1/12/Z (C.P.), SUNY Upstate Medical University, Upstate Foundation, One Square Mile of Hope Foundation, Carol M. Baldwin Breast Cancer Fund (D.B., M.M.), and Urology Care Foundation-American Urological Association (M.M.).

**Author contributions**

MRW, RAS, DMD, EM, ARB, RLM, NR, BP, CP, DB, and MM performed experiments. MRW, RAS, DMD, DB, OS, GB, SNL, DHG, MW, and MM designed experiments. MRW, RAS, and MM wrote the manuscript. MM conceived the project.

**Conflict of interest**

The authors declare that they have no conflict of interest.

**References**

Adams A, Gottschling DE, Kaiser CA, Stearns T (1997) Methods in yeast genetics. New York: Cold Spring Harbor Laboratory Press

Banerjee S, Crouse NR, Emmjrt RJ, Gianino SM, Gutmman DH (2011) Neurofibromatosis-1 regulates mTOR-mediated astrocyte growth and glioma formation in a TSC/Rheb-independent manner. Proc Natl Acad Sci USA 108: 15996–16001

Barrott JJ, Hughes PF, Osaka T, Yang XY, Hartman ZC, Loiselle DR, Spector NL, Neckers L, Rajaram N, Hu F, Ramanujam N, Vaidyanathan G, Zalutsky MR, Leyly HK, Haystead TA (2013) Optical and radiiodinated tethered Hsp90 inhibitors reveal selective internalization of ectopic Hsp90 in malignant breast tumor cells. Chem Biol 20: 1187–1197

Benvenuto G, Li S, Brown SJ, Braverman R, Vass WC, Cheadle JP, Halley DJ, Sampson JR, Wieniecke R, DeClue JE (2000) The tuberous sclerosis-1 (TSC1) gene product hamartin suppresses cell growth and augments the expression of the TSC2 product tuberin by inhibiting its ubiquitination. Oncogene 19: 6306–6316

Chadli A, Bruinsma ES, Stensgard B, Toft D (2008) Analysis of Hsp90 cochaperone interactions reveals a novel mechanism for TPR protein recognition. Biochemistry 47: 2850–2857

Chong-Kopera H, Inoki K, Li Y, Zhu T, Garcia-Gonzalo FR, Rosa JL, Guan KL (2006) TSC1 stabilizes TSC2 by inhibiting the interaction between TSC2 and the HERC1 ubiquitin ligase. J Biol Chem 281: 8313–8316

Cloutier P, Poitras C, Durand M, Helmati O, Fiola-Masson E, Bouchard A, Faubert D, Chabot B, Coulombe B (2017) R2TP/Prefoldin-like component RUVBL1/RUVBL2 directly interacts with ZNHIT2 to regulate assembly of US small nuclear ribonucleoprotein. Nat Commun 8: 15615

Cos MB, Johnson JL (2012) The Role of p23, Hop, Immunophilins, and Other Co-chaperones in Regulating Hsp90 Function. Methods Mol Biol 787: 45–66

Crino PB, Nathanson KL, Henske EP (2008) The tuberous sclerosis complex. N Engl J Med 355: 1345–1356

Dunn DM, Woodford MR, Truman AW, Jensen SM, Schulman J, Caza T, Remillard TC, Loiselle D, Wolfgerhe D, Blagg BS, Franco L, Haystead TA, Daturpalli S, Mayer MP, Trepel JB, Morgan RM, Prodromou C, Kron SJ, Panaretou B, Stetler-Stevenson WG, et al (2015) c-Abl mediated tyrosine phosphorylation of Aha1 activates its co-chaperone function in cancer cells. Cell Rep 12: 1006–1018

Gasteiger E, Gattiker A, Hoogland C, Ivanyi I, Appel RD, Bairoch A (2005) ExPASy: the proteomics server for in-depth protein knowledge and analysis. Nucleic Acids Res 33: 3784–3788

Henske EP, Jozwiak S, Kingswood JC, Sampson JR, Thiele EA (2016) Tuberous sclerosis complex. Nat Rev Dis Primers 2: 16035

Hoogeveen-Westerveld M, Exaltoto C, Maat-Kievit A, van den Ouweland A, Halley D, Nellist M (2010) Analysis of TSC1 truncations defines regions involved in TSC1 stability, aggregation and interaction. Biochim Biophys Acta 1802: 774–781

Hoogeveen-Westerveld M, Ekong R, Povey S, Karbassi I, Batish SD, den Dunnen JT, van Eeghen A, Thiele E, Mayer K, Dies K, Wen L, Thompson C, Sparagana SP, Davies P, Aalfs C, van den Ouweland A, Halley D, Nellist M (2012) Functional assessment of TSC1 missense variants identified in individuals with tuberous sclerosis complex. Hum Mutat 33: 476 – 479

Huang J, Manning BD (2008) The TSC1-TSC2 complex: a molecular switchboard controlling cell growth. Biochim J 412: 179–190

Li J, Richter K, Reinstein J, Buchner J (2013a) Integration of the accelerator Aha1 in the Hsp90 co-chaperone cycle. Nat Struct Mol Biol 20: 326–331
Li X, Srinivasan SR, Connan J, Ahmad A, Young ZT, Kabza AM, Zuiderweg ER, Sun D, Gesty-Wick J (2013) Analogs of the allosteric heat shock protein 70 (Hsp70) inhibitor, Mkt-077, as anti-cancer agents. ACS Med Chem Lett 4: 1042–1047

Meyer P, Prodromou C, Liao C, Hu B, Mark Roe S, Vaughan CK, Vlasic I, Panaretou B, Piper PW, Pearl LH (2004) Structural basis for recruitment of the ATPase activator Aha1 to the Hsp90 chaperone machinery. EMBO J 23: 511–519

Mollapour M, Bourboulia D, Beeke K, Woodford MR, Polier S, Hoang A, Chelluri R, Li Y, Guo A, Lee MJ, Fotooh-Abadi E, Khan S, Prince T, Miyajima N, Yoshida S, Tsutsumi S, Xu W, Panaretou B, Stetler-Stevenson WG, Bratslavsky G, et al (2014) Asymmetric Hsp90 N domain SUMOylation recruits Aha1 and ATP-competitive inhibitors. Mol Cell 53: 317–329

Neckers L, Workman P (2012) Hsp90 molecular chaperone inhibitors: are we there yet? Clin Cancer Res 18: 64–76

Panaretou B, Prodromou C, Roe SM, O’Brien R, Ladbury JE, Piper PW, Pearl LH (1998) ATP binding and hydrolysis are essential to the function of the Hsp90 molecular chaperone in vivo. EMBO J 17: 4829–4836

Panaretou B, Siligardi G, Meyer P, Maloney A, Sullivan JK, Singh S, Millson SH, Clarke PA, Naaby-Hansen S, Stein R, Cramer R, Mollapour M, Workman P, Piper PW, Pearl LH, Prodromou C (2002) Activation of the ATPase activity of hsp90 by the stress-regulated co-chaperone aha1. Mol Cell 10: 1307–1318

Prodromou C (2012) The ‘active life’ of Hsp90 complexes. Biochim Biophys Acta 1823: 614–623

Rettzlaff M, Hagen F, Mitschke L, Hessling M, Gugel F, Richter K, Buchner J (2010) Asymmetric activation of the hsp90 dimer by its co-chaperone aha1. Mol Cell 37: 344–354

Schopf FH, Biebl MM, Buchner J (2017) The HSP90 chaperone machinery. Nat Rev Mol Cell Biol 18: 345–360

Uhlmann EJ, Apicelli AJ, Baldwin RL, Burke SP, Bajenaru ML, Onda H, Kwaitkowski D, Gutmann DH (2002) Heterozygosity for the tuberous sclerosis complex (TSC) gene products results in increased astrocyte numbers and decreased p27-Kip1 expression in TSC2+/− cells. Oncogene 21: 4050–4059

Verba KA, Wang RY, Arakawa A, Liu Y, Shirotzu M, Yokoyama S, Agard DA (2016) Atomic structure of Hsp90-Cdc37-Cdk4 reveals that Hsp90 traps and stabilizes an unfolded kinase. Science 352: 1542–1547

Walton-Diaz A, Khan S, Bourboulia D, Trepel JB, Neckers L, Mollapour M (2013) Contributions of co-chaperones and post-translational modifications towards Hsp90 drug sensitivity. Future Med Chem 5: 1059–1071

Wang X, Venable J, LaPointe P, Hutt DM, Koulav AV, Coppinger J, Kurkan C, Kellner W, Matteson J, Plutner H, Riondan JR, Kelly JW, Yates JR III, Balch WE (2006) Hsp90 co-chaperone Aha1 downregulation rescues misfolding of CFTR in cystic fibrosis. Cell 127: 803–815

Woodford MR, Dunn DM, Blanden AR, Capriotti D, Loiselie D, Prodromou C, Panaretou B, Hughes PF, Smith A, Ackerman W, Haystead TA, Loh SN, Bourboulia D, Schmidt LS, Marston Linehan W, Bratslavsky G, Mollapour M (2016) The FNIP co-chaperones decelerate the Hsp90 chaperone cycle and enhance drug binding. Nat Commun 7: 12037

Woodford MR, Truman AW, Dunn DM, Jensen SM, Cotran R, Bullard R, Abouelleil M, Beeke K, Wierzbicki S, Post DE, Caza T, Tsutsumi S, Panaretou B, Kron SJ, Trepel JB, Landas S, Prodromou C, Shapiro O, Stetler-Stevenson WG, et al (2016) Mps1 mediated phosphorylation of Hsp90 confers renal cell carcinoma sensitivity and selectivity to Hsp90 inhibitors. Cell Rep 14: 872–884

Xu Y, Singer MA, Lindquist S (1999) Maturation of the tyrosine kinase c-src as a kinase and as a substrate depends on the molecular chaperone Hsp90. Proc Natl Acad Sci USA 96: 109–114

Xu W, Mollapour M, Prodromou C, Wang S, Scroggins BT, Palchick Z, Beeke K, Siderius M, Lee MJ, Covillion A, Trepel JB, Miyata Y, Matts R, Neckers L (2012) Dynamic tyrosine phosphorylation modulates cycling of the HSP90-P50(CDC37)-AHA1 chaperone machine. Mol Cell 47: 434–443

Yang J, Campobasso N, Biju MP, Fisher K, Pan XQ, Cottom J, Galbraith S, Ho T, Zhang H, Hong X, Ward P, Hofmann G, Siegfried B, Zappacosta F, Washio Y, Cao P, Qu J, Bertrand S, Wang DY, Head MS, et al (2011) Discovery and characterization of a cell-permeable, small-molecule c-Abi kinase activator that binds to the myristoyl binding site. Chem Biol 18: 177–186

Ying W, Du Z, Sun L, Foley KP, Proia DA, Blackman RK, Zhou D, Inoue T, Tatsuta N, Sang J, Ye S, Acquaviva J, Ogawa LS, Wada Y, Barsoum J, Koya K (2012) Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy. Mol Cancer Ther 11: 475–484

Youker RT, Walsh P, Heilharz T, Lithgow T, Brodsky JL (2004) Distinct roles for the Hsp40 and Hsp90 molecular chaperones during cystic fibrosis transmembrane conductance regulator degradation in yeast. Mol Biol Cell 15: 4785–4797

Zeng LH, Xu L, Gutmann DH, Wong M (2008) Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex. Ann Neurol 63: 444–453

Zeng LH, Rensing NR, Zhang B, Gutmann DH, Gambello MJ, Wong M (2011) Tsc2 gene inactivation causes a more severe epilepsy phenotype than Tsc1 inactivation in a mouse model of tuberous sclerosis complex. Hum Mol Genet 20: 445–454

License: This is an open access article under the terms of the Creative Commons Attribution 4.0 License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.